{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05161429",
            "orgStudyIdInfo": {
                "id": "2021P001171"
            },
            "organization": {
                "fullName": "Brigham and Women's Hospital",
                "class": "OTHER"
            },
            "briefTitle": "BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes",
            "officialTitle": "BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes",
            "acronym": "BESTMED",
            "therapeuticArea": [
                "Endocrinology"
            ],
            "study": "bestmed-observational-evaluation-of-second-line-therapy-medications-in-diabetes"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-07-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-06-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-11-23",
            "studyFirstSubmitQcDate": "2021-12-03",
            "studyFirstPostDateStruct": {
                "date": "2021-12-17",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-06-16",
            "lastUpdatePostDateStruct": {
                "date": "2023-06-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Alexander Turchin",
                "investigatorTitle": "Associate Professor of Medicine",
                "investigatorAffiliation": "Brigham and Women's Hospital"
            },
            "leadSponsor": {
                "name": "Brigham and Women's Hospital",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Patient-Centered Outcomes Research Institute",
                    "class": "OTHER"
                },
                {
                    "name": "Baylor College of Medicine",
                    "class": "OTHER"
                },
                {
                    "name": "Baylor Scott and White Research Institute",
                    "class": "UNKNOWN"
                },
                {
                    "name": "The Cleveland Clinic",
                    "class": "OTHER"
                },
                {
                    "name": "HealthCore, Inc.",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Humana Inc.",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Massachusetts General Hospital",
                    "class": "OTHER"
                },
                {
                    "name": "Medical Outcomes Management",
                    "class": "UNKNOWN"
                },
                {
                    "name": "University of Iowa",
                    "class": "OTHER"
                },
                {
                    "name": "Allina Health",
                    "class": "UNKNOWN"
                },
                {
                    "name": "Intermountain Health Care, Inc.",
                    "class": "OTHER"
                },
                {
                    "name": "Marshfield Clinic",
                    "class": "UNKNOWN"
                },
                {
                    "name": "Medical College of Wisconsin",
                    "class": "OTHER"
                },
                {
                    "name": "University of Missouri-Columbia",
                    "class": "OTHER"
                },
                {
                    "name": "University of Utah",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "An observational study of electronic patient data to compare diabetes medications and to determine which ones offer the best balance of risks and benefits.",
            "detailedDescription": "Type 2 diabetes is an increasingly common disease that affects more than 10 percent of adults in the United States. Multiple medications are available to treat this condition. However, many of these medications have never been directly compared against one another, which makes it unclear which medication is the best to use.\n\nInvestigators will use a large database of electronic patient data to compare diabetes medications to determine which ones offer the best balance of risks and benefits. This database will draw from several large healthcare institutions and health insurance companies that collectively pull from a patient population of over 130 million across all major regions of the United States. Investigators will study adults aged 30 or older who have type 2 diabetes and are at moderate risk of heart attacks and strokes, and who are starting a second diabetes medication (after metformin). Investigators will use clinical trial emulation, a cutting-edge statistical technique, to compare the following classes of diabetes medications: (1) DPP4 inhibitors (alogliptin, linagliptin, sitagliptin, or saxagliptin); (2) GLP1 receptor agonists (dulaglutide, exenatide, liraglutide, or semaglutide); (3) basal insulin (degludec, detemir, glargine, or NPH); (4) SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin); and (5) sulfonylureas (glimepiride, glipizide, or glyburide).\n\nTo determine which diabetes medications provide the greatest benefit to patients, investigators will compare how much they reduce the risks of the following \\\\conditions: (1) heart attack; (2) heart failure; (3) stroke; (4) kidney disease; (5) eye disease; and (6) liver disease. To allow patients with diabetes and their doctors to make fully informed decisions about which diabetes medication to take, investigators will also compare these medications' risks of the following possible side effects: (1) low blood sugar; (2) kidney infection; (3) severe skin infections in the genital area; (4) foot/leg amputations; (5) broken bones; (6) pancreatitis (i.e., severe inflammation of the pancreas); (7) pancreatic cancer; (8) thyroid cancer; and (9) death from causes other than heart attacks or strokes.\n\nIn order to minimize the risk of bias and confounding, the analysis will be conducted using causal inference techniques, by emulating a randomized clinical trial (including both intention-to-treat and per-protocol analyses), while incorporating rigorous data quality checks."
        },
        "conditionsModule": {
            "conditions": [
                "Diabetes Mellitus, Type 2"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "RETROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 550000,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "DPP4",
                    "description": "Patients receiving second line diabetes treatment with dipeptidyl peptidase-4 inhibitors (DPP4) following metformin",
                    "interventionNames": [
                        "Drug: DPP4"
                    ]
                },
                {
                    "label": "GLP1-RA",
                    "description": "Patients receiving second line diabetes treatment with glucagon-like peptide-1 receptor agonists (GLP1-RA) following metformin",
                    "interventionNames": [
                        "Drug: GLP-1 receptor agonist"
                    ]
                },
                {
                    "label": "Basal insulin",
                    "description": "Patients receiving second line diabetes treatment with basal insulin following metformin",
                    "interventionNames": [
                        "Drug: Basal Insulin"
                    ]
                },
                {
                    "label": "SLGT2",
                    "description": "Patients receiving second line diabetes treatment with sodium-glucose cotransporter-2 inhibitors (SLGT2) following metformin",
                    "interventionNames": [
                        "Drug: SLGT2"
                    ]
                },
                {
                    "label": "SU",
                    "description": "Patients receiving second line diabetes treatment with sulfonylureas (SU) following metformin",
                    "interventionNames": [
                        "Drug: SU"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "DPP4",
                    "description": "Dipeptidyl peptidase-4 inhibitors (DPP4) including alogliptin, linagliptin, sitagliptin, and saxagliptin",
                    "armGroupLabels": [
                        "DPP4"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "GLP-1 receptor agonist",
                    "description": "Glucagon-like peptide-1 receptor agonists (GLP1-RA) including dulaglutide, exenatide, liraglutide and semaglutide",
                    "armGroupLabels": [
                        "GLP1-RA"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Basal Insulin",
                    "description": "degludec, detemir, glargine and NPH",
                    "armGroupLabels": [
                        "Basal insulin"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "SLGT2",
                    "description": "Sodium-glucose cotransporter-2 inhibitors (SLGT2) including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin",
                    "armGroupLabels": [
                        "SLGT2"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "SU",
                    "description": "Sulfonylurea (SU) including glimepiride, glipizide, and glyburide",
                    "armGroupLabels": [
                        "SU"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "4-point major adverse cardiac events (MACE)",
                    "description": "Includes: a) death from cardiovascular causes b) non-fatal myocardial infarction (MI) c) non-fatal stroke and d) hospitalization for heart failure (HF)",
                    "timeFrame": "Follow-up begins 30 days after enrollment and ends at the earliest of a) the first study outcome; b) study end or c) loss to follow-up. Maximum duration of follow-up will be 10.5 years."
                },
                {
                    "measure": "3-point major adverse cardiac events (MACE)",
                    "description": "Includes: a) death from cardiovascular causes as reported in the National Death Index b) non-fatal MI and c) non-fatal stroke",
                    "timeFrame": "Follow-up begins 30 days after enrollment and ends at the earliest of a) the first study outcome; b) study end or c) loss to follow-up. Maximum duration of follow-up will be 10.5 years."
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Adverse outcomes",
                    "description": "Includes a) severe hypoglycemia b) severe urinary tract infection (UTI) c) Fournier's gangrene d) lower extremity amputation e) bone fracture f) diabetic ketoacidosis (DKA) g) pancreatitis h) pancreatic cancer i) medullary thyroid cancer j) non-cardiovascular death",
                    "timeFrame": "Follow-up begins 30 days after enrollment and ends at the earliest of a) the first study outcome; b) study end or c) loss to follow-up. Maximum duration of follow-up will be 10.5 years."
                },
                {
                    "measure": "Severe clinical outcomes",
                    "description": "Includes: a) hospitalization for \\>= 30 days with any of the primary or secondary outcome endpoints as the primary or admitting diagnosis b) ICU admission with any of the primary or secondary outcome endpoints as the primary or admitting diagnosis or c) death from any cause",
                    "timeFrame": "Follow-up begins 30 days after enrollment and ends at the earliest of a) the first study outcome; b) study end or c) loss to follow-up. Maximum duration of follow-up will be 10.5 years."
                },
                {
                    "measure": "Non-cardiovascular outcomes",
                    "description": "Includes a) nephropathy b) diabetic retinopathy requiring treatment c) non-alcoholic fatty liver disease (NAFLD) with advanced fibrosis / nonalcoholic steatohepatitis (NASH)",
                    "timeFrame": "Follow-up begins 30 days after enrollment and ends at the earliest of a) the first study outcome; b) study end or c) loss to follow-up. Maximum duration of follow-up will be 10.5 years."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Individuals meeting the following criteria between January 1, 2015 and December 31, 2021:\n\n* Diabetes mellitus (DM) type II\n* HbA1c of 7-11% within the past year\n* Monotherapy with metformin for at least 3 months\n* No prior non-metformin outpatient diabetes therapy\n* Aged \u226530y\n* At \"moderate\" risk of ASCVD\n\n  * Men aged \u226535y and women aged \u226545y with no history\\* of stroke, myocardial infarction, revascularization, or heart failure hospitalization\n  * Men aged 30-34 and women aged 30-44 with history\\* of hypertension, hyperlipidemia, retinopathy, kidney disease or neuropathy\n* estimated glomerular filtration rate (eGFR) \u2265 45 ml/min/1.73m2 within the past 3 years\n* Not pregnant at time 0\n* No history\\* of institutionalization with a diagnosis of dementia, metastatic cancer, end stage lung disease, end stage liver disease, pancreatitis, medullary thyroid cancer or severe UTIs\n* Engagement with the healthcare system: enrollment for at least 12 months and attendance of at least one outpatient encounter in the prior 12 months\n\n(\\*) History will be derived from at least 12 months of EHR and claims prior to time zero and will use all available EHR and claims data between January 1, 2014 and time zero",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "30 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "The study population is adults aged 30 or older who have type 2 diabetes and are at moderate risk of Atherosclerotic Cardiovascular Disease (ASCVD), and who are starting a second diabetes medication (after metformin). Patients from collaborating institutions will be included in the analysis based on study population inclusion and exclusion criteria.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Emma Hegermiller, MS",
                    "role": "CONTACT",
                    "phone": "617-732-5661",
                    "email": "emma@bestmed.org"
                },
                {
                    "name": "Alexander Turchin, MD, MS",
                    "role": "CONTACT",
                    "phone": "617-732-5661",
                    "email": "aturchin@bwh.harvard.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Alexander Turchin, MD, MS",
                    "affiliation": "Brigham and Women's Hospital",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "HealthCore, Inc.",
                    "status": "RECRUITING",
                    "city": "Wilmington",
                    "state": "Delaware",
                    "zip": "19801",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Vincent Willey, PharmD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.74595,
                        "lon": -75.54659
                    }
                },
                {
                    "facility": "Humana",
                    "status": "RECRUITING",
                    "city": "Lexington",
                    "state": "Kentucky",
                    "zip": "40512-4611",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Vinit Nair, MS, RPh",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.98869,
                        "lon": -84.47772
                    }
                },
                {
                    "facility": "Brigham and Women's Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02115",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alexander Turchin, MD, MS",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Greater Plains Collaborative",
                    "status": "RECRUITING",
                    "city": "Beachwood",
                    "state": "Ohio",
                    "zip": "44122",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ryan Carnahan, PhD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4645,
                        "lon": -81.50873
                    }
                },
                {
                    "facility": "Baylor Scott & White",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75246",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Heather Kitzman Carmichael, PhD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "9603539",
                    "type": "BACKGROUND",
                    "citation": "Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998 May 12;97(18):1837-47. doi: 10.1161/01.cir.97.18.1837."
                },
                {
                    "pmid": "8266381",
                    "type": "BACKGROUND",
                    "citation": "D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke. 1994 Jan;25(1):40-3. doi: 10.1161/01.str.25.1.40."
                },
                {
                    "pmid": "10371227",
                    "type": "BACKGROUND",
                    "citation": "Kannel WB, D'Agostino RB, Silbershatz H, Belanger AJ, Wilson PW, Levy D. Profile for estimating risk of heart failure. Arch Intern Med. 1999 Jun 14;159(11):1197-204. doi: 10.1001/archinte.159.11.1197."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003920",
                    "term": "Diabetes Mellitus"
                },
                {
                    "id": "D000003924",
                    "term": "Diabetes Mellitus, Type 2"
                }
            ],
            "ancestors": [
                {
                    "id": "D000044882",
                    "term": "Glucose Metabolism Disorders"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7119",
                    "name": "Diabetes Mellitus, Type 2",
                    "asFound": "Diabetes Mellitus, Type 2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7115",
                    "name": "Diabetes Mellitus",
                    "asFound": "Diabetes",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M25403",
                    "name": "Glucose Metabolism Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000097789",
                    "term": "Glucagon-Like Peptide-1 Receptor Agonists"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007004",
                    "term": "Hypoglycemic Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1691",
                    "name": "Sodium-Glucose Transporter 2 Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M258082",
                    "name": "Empagliflozin",
                    "relevance": "LOW"
                },
                {
                    "id": "M11667",
                    "name": "Metformin",
                    "relevance": "LOW"
                },
                {
                    "id": "M9043",
                    "name": "Glucagon",
                    "relevance": "LOW"
                },
                {
                    "id": "M26997",
                    "name": "Glucagon-Like Peptide 1",
                    "relevance": "LOW"
                },
                {
                    "id": "M353561",
                    "name": "Semaglutide",
                    "relevance": "LOW"
                },
                {
                    "id": "M10365",
                    "name": "Insulin",
                    "relevance": "LOW"
                },
                {
                    "id": "M173166",
                    "name": "Insulin, Globin Zinc",
                    "relevance": "LOW"
                },
                {
                    "id": "M335",
                    "name": "Sitagliptin Phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M419",
                    "name": "Liraglutide",
                    "relevance": "LOW"
                },
                {
                    "id": "M348449",
                    "name": "Dapagliflozin",
                    "relevance": "LOW"
                },
                {
                    "id": "M3401",
                    "name": "Glucagon-Like Peptide-1 Receptor Agonists",
                    "asFound": "Boostrix",
                    "relevance": "HIGH"
                },
                {
                    "id": "M445",
                    "name": "Linagliptin",
                    "relevance": "LOW"
                },
                {
                    "id": "M349",
                    "name": "Insulin Detemir",
                    "relevance": "LOW"
                },
                {
                    "id": "M347",
                    "name": "Insulin Glargine",
                    "relevance": "LOW"
                },
                {
                    "id": "M27957",
                    "name": "Dipeptidyl-Peptidase IV Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M258626",
                    "name": "Dulaglutide",
                    "relevance": "LOW"
                },
                {
                    "id": "M331",
                    "name": "Canagliflozin",
                    "relevance": "LOW"
                },
                {
                    "id": "M1726",
                    "name": "Exenatide",
                    "relevance": "LOW"
                },
                {
                    "id": "M9023",
                    "name": "Glipizide",
                    "relevance": "LOW"
                },
                {
                    "id": "M228152",
                    "name": "Saxagliptin",
                    "relevance": "LOW"
                },
                {
                    "id": "M252104",
                    "name": "Glimepiride",
                    "relevance": "LOW"
                },
                {
                    "id": "M9017",
                    "name": "Glyburide",
                    "relevance": "LOW"
                },
                {
                    "id": "M247106",
                    "name": "Alogliptin",
                    "relevance": "LOW"
                },
                {
                    "id": "M263808",
                    "name": "Ertugliflozin",
                    "relevance": "LOW"
                },
                {
                    "id": "M10054",
                    "name": "Hypoglycemic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                },
                {
                    "abbrev": "AnObAg",
                    "name": "Anti-Obesity Agents"
                },
                {
                    "abbrev": "AnArAg",
                    "name": "Anti-Arrhythmia Agents"
                }
            ]
        }
    },
    "hasResults": false
}